Filtered By:
Condition: Disability
Management: National Institutes of Health (NIH)
Countries: Spain Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol
Introduction Stroke is a serious public health problem, given it is a major cause of disability worldwide despite the spread of recanalisation therapies. Enhancement of brain plasticity with stem cell administration is a promising innovative therapy to reduce sequelae in these patients. Methods and analysis We have developed a phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial protocol to evaluate the safety and efficacy of intravenous administration of allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs) in patients with acute ischaemic stroke, concurrently with conventional...
Source: BMJ Open - August 9, 2021 Category: General Medicine Authors: de Celis-Ruiz, E., Fuentes, B., Moniche, F., Montaner, J., Borobia, A. M., Gutierrez-Fernandez, M., Diez-Tejedor, E. Tags: Open access, Neurology Source Type: research

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLASummaryBackgroundS44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitabi...
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research